Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laksh Trust31-05-2018
31-05-2018
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laksh Trust23-05-2018
US FDA Inspection At Alembic Pharmaceuticals API Facility At Karkhadi.
We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals API Facility located at Karkhadi from 14th May, 2018 to 18th May, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with one observation. The Company is preparing the response to the observation, which will be submitted to the US FDA shortly....18-05-2018
Audited Financial Results Of The Company For The Financial Year Ended 31St March, 2018.
Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2018.16-05-2018
Alembic Pharma posts Q4 profit of Rs93.79 crore
Alembic Pharma's consolidated revenue from operations stood at Rs853.31 crore for the fourth quarter. It was Rs741.35 crore for the same period year ago16-05-2018
Corporate Action-Board approves Dividend
Recommended a dividend of Rs. 4.00 (200%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting.16-05-2018
Board Meeting-Outcome of Board Meeting
(i) Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2018. (ii) Recommended a dividend of Rs. 4.00 (200%) per Equity Share having face value of Rs. 2/- each. The Statutory Auditors of the Company, M/s. K. S. Aiyar & Co., has issued audit report with unmodified opinion on the Consolidated and Standalone Audited Financial Results of the Company for the financial year ended 31st March, 2018....16-05-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 16th May, 2018 as per enclosed details. Kindly take the same on record.07-05-2018
Board to consider FY18 results & Dividend on May 16, 2018
Alembic Pharmaceuticals Ltd has informed BSE that a Meeting of Board of Directors of the Company shall be held on May 16, 2018, inter alia, to transact the following business:1. To consider and approve Audited Financial Results of the Company for the financial year ended March 31, 2018.2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended March 31, 2018....07-05-2018